



ASX ANNOUNCEMENT

16 January 2014

Experienced stem cell product developer to join Cynata

Cynata Therapeutics Ltd (ASX: CYP), announced today the appointment of Dr Kilian Kelly as Vice President, Product Development. Dr Kelly will be a member of Cynata's executive management team and will lead the regulatory, pre-clinical and clinical development of the Company's proprietary Cymerus™ mesenchymal stem cell (MSC) product pipeline.

Chief Executive Officer of Cynata Therapeutics, Dr Ross Macdonald said: "Kilian has prominent expertise in stem cell product development for therapeutic regenerative medicine applications and significant pre-clinical and clinical development experience in the pharmaceutical industry. We are very pleased to welcome him as a member of our team. His strong and highly relevant experience in successful product development programs and regulatory approval is the precise expertise we seek to advance the development of our Cymerus™ stem cell technology through into human clinical trials."

Most recently, Dr. Kelly served as Senior Director, Drug Development at Biota Pharmaceuticals Inc. and led the regulatory development of Biota's product programs, involving direct interaction with regulatory agencies in major global markets, including the FDA in the USA. Prior to joining Biota he was Vice President, Regulatory and Clinical at Mesoblast Ltd where he managed regulatory affairs and clinical development of that company's stem cell products, including contributing to five successful INDs in the USA. Dr Kelly has also held a variety of regulatory and project management positions with Kendle International, Amgen and AstraZeneca.

"I am delighted to be joining Cynata Therapeutics and I look forward to building upon the significant momentum of the Cymerus™ product development program and bringing it to a successful outcome," said Dr. Kelly. "The therapeutic use of stem cells, and particularly MSCs, is one of the most exciting developments in medicine in many years. The inherent scalability of the Cymerus™ technology and thus its capacity for commercial manufacture has the potential to create a new standard in the emergent area of stem cell therapeutics" Dr Kelly went on to say.

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email dr.washer@gmail.com

About Cynata Therapeutics (ASX:CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165, Hawthorn North, Victoria 3122 **T:** + 613 9824 5254 **F:** + 613 9822 7735 **E:** admin@cynata.com
W: www.cynata.com **ABN** - 98 104 037 372